Article

Second-line erlotinib for non-small-cell lung cancer.

Medical Oncology Unit, Ospedale Vito Fazzi, Lecce, Italy.
The Lancet Oncology (Impact Factor: 25.12). 04/2012; 13(4):e141-2; author reply e142. DOI: 10.1016/S1470-2045(12)70113-4
Source: PubMed
0 Bookmarks
 · 
140 Views

Full-text

Download
73 Downloads
Available from
May 30, 2014